Teva Pharmaceuticals USA recalls Glipizide Extended-Release Tablets (anti-diabetic agent), 5 mg, packaged in 30-unit dose blister pack per carton, Rx on…

Recall date

August 2, 2017

Source

U.S. Food & Drug Administration (FDA) — enforcement report

Recall number

D-1058-2017

FDA classification

Class III

Brand / firm

Teva Pharmaceuticals USA

Sold / distributed

Product distributed to OH, IL, PA, MI, VA and CT

Why it was recalled

Failed Moisture Limits: out of specification test results for water content obtained during stability testing.

Class III means the product violates regulations but is not likely to cause harm.

What was recalled

Glipizide Extended-Release Tablets (anti-diabetic agent), 5 mg, packaged in 30-unit dose blister pack per carton, Rx only, Mfd for: Watson Laboratories, Inc., Corona, CA 92880, Mfd by: Patheon Pharmaceuticals, Inc., Cincinnati, OH 43215, NDC 0591-0844-15